

Sheffield Traffic Light Drugs List October 2024

Note: the BNF numbering system is based on the BNF legacy

Refer to the user guide for classification rationale

Remember : Control + F (see user guide for how to) to search this list

BNF Section	Drug	Rational :	Notes	
		see		
		introduction		Relevant links
4.10.1	Acamprosate		If initiated in primary care, to be prescribed by a GP/prescriber with special interest OR	
			experience in alcohol relapse prevention and in conjunction with an offer of	
			psychological interventions. See the prescribing guideline for more information.	
7.4.5	Alprostadil	1, 2	If SLS criteria not met: a GP may provide a private prescription (detailed in HSC)	
1.4.5		1, 2	1999/148) See also entry in amber section.	
	Alprostadil		SLS criteria applies - prescriptions may be issued for patients eligible for NHS treatment	HSC 1999/177
7.4.5		1	(as per SI 2004 No 629), otherwise RED. Note - Patients with Severe Distress are not	
			covered by SLS criteria (as detailed in HSC 1999/177).	
2.3.2	Amiodarone	1, 2, 3	Amiodarone SCG	
4.2.1	Amisulpride	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
	Anastrozole		Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on	
8.3.4.1		1, 2	prescribing for a specified duration, for advice on drug management see: <u>Referral and</u>	
			Management Guidelines for Breast Cancer. See also, section on ibandronic acid.	
OTC Preparations	Anti-fungal nail paints	4	See <u>Sheffield STOP list</u> for full details and note circumstances where prescribing may	
			be appropriate.	
	Apixaban - For prevention of venous thromboembolism after total	1, 5	See Amber and Green sections for other indications.	NICE TA245
2.8.2	hip and knee replacement in adults. Note: full course to be			
	provided by secondary care.			
2.8.2	Apixaban for the treatment and secondary prevention of deep	1	See Red and Green sections for other indications.	NICE TA341
	vein thrombosis and pulmonary embolism			
2.8.2	Apixaban for preventing stroke and systemic embolism in people		Local guidelines for the prevention of stroke in non-valvular atrial fibrillation. See Red	NICE TA275
101	with non-valvular atrial fibrillation		and Amber sections for other indications.	
4.2.1	Aripiprazole	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
4.2.3	Asenapine	1	SHSC have also stated that they would not be routinely initiating prescriptions.	
OTC Preparations	Aspirin 300mg for acute pain in adults	4	See <u>Sheffield STOP list</u> for full details and note circumstances where prescribing may	
	Atomovating		be appropriate.	
4.4	Atomoxetine	1, 2	SCG for ADHD in Children and Adults	
	Avacopan	1, 5	NHSE commissioned.	NICE TA825

	For treating	Avatrombopag			NICE TA626
Process Neuron Participant 1, 5 Participant 1 Paritipant	thrombocytopenia				
Bisessen needing at proceed needing at proceed needing at proceed needing at the proceed needing at the proceed needing at the proceed needing at the proceed needing at the proceeding at					
Internet investive Decodaria Azathioprine 1,5 When no agreed SCP available. Image: Comparison of the second			1, 5		
Bit 3 Azathioprine Link Mathematical State Mice and					
10.1.3 Azathioprine 1,5 When no greed SCP available. Image: SCP available. 10.1.3 Azathioprine 1,2,3 Bempedoic Acid (Nilemdo*) Image: SCP available. Sce also Lpd/ Image: SCP available. Image: SCP available. Sce also Lpd/ Image: Sce also Lpd/					
10.1.3 Azathoprine 1, 2, 3 Azathoprine and Mercaptourine SCP Image: Construction of the program of primary hypercholesterolestream or mixed dyslipidemia, as an option for lipid specialist to consider. See also bempedoic acid in Green section. 2.12 Bempedoic Acid NICE TA694 Creen NCIV in combination with ezertimibe and in line with the updated lipid quidelines of the RSECONARY prevention of cardiovascular disease in adults. See also bempedoic acid in Stream section. See also Lipid. 2.12 Bempedoic Acid NICE TA694 Creen NCIV in combination of NCIV. See Lipid. dominisation for disease in adults. See also bempedoic acid in SECONARY prevention of cardiovascular disease in adults. See also bempedoic acid in Amber section for monotherapy. See also Lipid. 2.12 Benperidol 1, 2 NICE TA738 NICE TA738 2.24 Beta Interferon 1, 5 NIMES commissioned. NICE TA738 2.12 Bezaribrate 1, 5 Should not be prescribed in primary care as an oral anticancer medication. In line with NPSA Mark, Exceptions include oral anticancer medications where a shared care protocol exists. NICE TA738 2.12 Bezaribrate 1, 2 Hormonal Management of Prostatic Cancer SCP NICE TA738 2.12 Becaribrate 1, 2 Hormonal Management of Prostatic Cancer SCP NICE TA283 3.3.2 Bocoprevir for the treatament of genotype 1 c		Azathionrine	15	When no agreed SCP available	
Bempedoic Acid (Nilemdo*) Image: Consider Section 1 Monotherapy, for the management of primary hypercholesterolaemia or mixed dysipidaemia, as an option for lipid specialist to consider. See also bempedoic acid in Green ORLV in combination with exatimble and in line with the updated lipid juicelines. See also Lipid. Optimisation for the Section NULY in combination with exatimble and in line with the updated lipid juicelines. See also Lipid. Optimisation for the Section for monotherapy. See also Lipid. Optimisation for the Section for BOTH the primary and secondary prevention of CVD. See Lipid optimisation for the Section for monotherapy. See also bempedoic acid disease in adults. See also bempedoic					
2.12 1 dysiptionation or lipid specialist to consider. See also bempedoic acid in dysiptionation with exertine and in line with the updated lipid guidelines for BOTH the primary and secondary prevention of CVD. See Lipid optimisation for the SECONDARY prevention of CVD. See Lipid optimisation for the SECONDARY prevention of cardiovascular disease in adults. See also bempedoic acid in Amber section for monotherapy. See also Lipid. 2.12 Benperidol 1, 2 This includes depot antipsychotics. Specialist to initiate and stabilise dose. See also Lipid. 2.4.1 Benperidol 1, 2 This includes depot antipsychotics. Specialist to initiate and stabilise dose. NCE TA738 8.2.4 Beta Interferon 1, 5 NHSE commissioned. NCE TA738 8.1 1.5 Should not be prescribed in primary care as an oral anticancer medication, in line with Pisc Alert. Exceptions include oral anti cancer medication, in line with Pisc Alert. Exceptions include oral anti cancer medication of a lipid cipic specialist. NICE TA738 8.3.4.2 Bicalutamide 1, 2 Hormonal Management of Prostatic Cancer SCP NICE TA253 3.3.2 Boceprevir for the treatment of genotype 1 chronic hepatitits C 1, 5 For management of Prostatic Cancer SCP NICE TA253 13.6.3 Briwonidine tartrate (Mirvaso®) 1 Aleges in Children SCG Aspelie/terment.and reacovery-team See MHRA uzdreadvascul	10.1.0		1, 2, 0	Monotherapy, for the management of primary hypercholesterolaemia or mixed	
Bempedoic Acid NICE TA694 See also Lipid. 2.12 Green, ONLY in combination with exertimble and in line with the updated lipid guidelines. See also Lipid. See also Lipid. 4.2.1 Benperiol 1,2 This includes depot antipsychotics. Specialist to initiate and stabilise dose. PPIMARY prevention of CVD. See also bempedoic and in Amber section for monotherapy. Mice TA788 8.2.4 Beta Interferon 1,5 NHSE commissioned. NICE TA788 8.2.4 Beta Interferon 1,5 Should not be prescribed in primary care as an oral anticancer medication, in line with protocol exists. NICE TA788 8.1 Bezafibrate 1,5 Should not be prescribed in primary care as an oral anticancer medication, in line with protocol exists. NICE TA788 8.3.4.2 Bicalutamide 1,2 Hornonal Management of Prostatic Cancer SCP NICE TA253 8.3.4.2 Bicalutamide 1,2 Hornonal Management of Prostatic Cancer SCP NICE TA253 1.6.3 Brimonidine tartrate (Mirvaso®) 1 AlfRA See olid condispersible NICE TA253 1.5.2 Burgenoriphine 1,5 Hitp://www.england.ths.uk/commissionng/wp-content/uploads/sites/12/2015/06/hep-c- so priotal with we update antis word usual	2.12		1		
2.12 for BOTH the primary and secondary prevention of CVD. See Lind optimisation for the SECONDARY prevention of CVD. See Lind optimisation for the PRIMARY provides a constraint of the SECONDARY prevention of CVD. See Lind optimisation for the PRIMARY provides a constraint of the SECONDARY prevention of CVD. See Lind optimisation for the PRIMARY provides a constraint of the SECONDARY prevention of CVD. See Lind optimisation for the PRIMARY prevention of CVD. See Lind optin Sec Lind opting Prevention of CVD. See L					
2.12 SECONDARY prevention of cardiovascular disease in adults. See also bempedoic acid of cardiovascular disease in adults. See also bempedoic acid of cardiovascular disease in adults. See also bempedoic acid of cardiovascular disease in adults. See also bempedoic acid disease in adults. See also adults. See also bempedoi		Bempedoic Acid NICE TA694			
4.2.1 Benperidol 1, 2 This includes depot antipsychotics. Specialist to initiate and stabilise dose. of cardiovascular disease in adult disease in adult disease in adult. 8.2.4 Beta Interferon 1, 5 NHSE commissioned. NICE TA738 8.1 Besta Interferon 1, 5 Should not be prescribed in primary care as an oral anticancer medication, in line with the state of the protocol exists. NICE TA738 8.1 Besta Interferon 1, 5 NPSA Alert. Exceptions include oral anti cancer medication, in line with the protocol exists. NICE TA738 8.1 Bestafibrate 1, 5 NPSA Alert. Exceptions include oral anti cancer medication, of a lipid clinic specialist. NICE TA738 8.3.4.2 Bicalutamide 1, 2 Hornonal Management of Prostatic Cancer SCP NICE TA253 8.3.3.2 Boceprevir for the treatment of genotype 1 chronic hepatitis C 1, 5 Intitiz/Www.england.nb.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-c- NICE TA253 13.6.3 Brivaracetam 1 Epileps in Children SCG See MHRA unds 14.3.1 Brivaracetam 1 Epileps in Children SCG See MHRA unds 15.2 Budesonide Orodispersible 1 As opioid substitution therapy. htttps://www.shsc.nhs.uk/services/opilates-serv					optimisation for the
4.2.1 Benperidol 1, 2 This includes depot antipsychotics. Specialist to initiate and stabilise dose. NICE TA738 8.2.4 Beta Interferon 1, 5 NHSE commissioned. NICE TA738 8.2.4 Beta Interferon 1, 5 Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert, Exceptions include oral anti cancer medication, in line with NPSA Alert, Exceptions include oral anti cancer medication, in line with NPSA Alert, Exceptions include oral anti cancer medication or a lipid clinic specialist. NICE TA738 8.1 Bezafibrate 1, 2 Hormonal Management of Prostatic Cancer SCP NICE TA233 8.3.4.2 Bicalutamide 1, 2 Hormonal Management of Prostatic Cancer SCP NICE TA253 3.3.2 Boceprevir for the treatment of genotype 1 chronic hepatitis C 1, 5 http://www.england.nbs.w/commissioning/wp-content/uploads/sites/12/2015/06/hep-cc NICE TA253 13.6.3 Brimonidine tartrate (Mirvaso®) 1 For management of rostacea. See Drug Safety Alerts on risk of exacerbation of rostacea See MHRA upd: set manu set missioning/wp-content/uploads/sites/12/2015/06/hep-cc NICE TA253 14.8.1 Brivaracetam 1 Epilepsy in Children SCG See MHRA upd: set missioning/wp-content/uploads/sites/12/2015/06/hep-cc See MHRA upd: set manu set missioning/wp-content/uploads/sites/12/2015/06/	2.12				PRIMARY prevention
4.2.1 Benperidol 1, 2 This includes depot antipsychotics. Specialist to initiate and stabilise dose. NICE TA738 Beta Interferon 1, 5 NHSE commissioned. NICE TA738 Beta Interferon 1, 5 NHSE commissioned in primary care as an oral anticancer medication, in line with NSE Alert. Exceptions include oral anti cancer medication, in line with NSE Alert. Exceptions include oral anti cancer medication, in line with NSE Alert. Exceptions include oral anti cancer medication, in line with NSE Alert. Exceptions include oral anti cancer medication, in line with NSE Alert. Exceptions include oral anti cancer medication, in line with NSE Alert. Exceptions include oral anti cancer medication, in line with NSE Alert. Exceptions include oral anti cancer medication of a lipid clinic specialist. 2.12 Bezafibrate For hyperfrighyceridemia and/or mixed dyslipidaemia; however, use in this cohort of protocol exists. 8.3.4.2 Bicalutamide 1, 2 Hormonal Management of Prostatic Cancer SCP NICE TA253 6.3.3.2 Boceprevir for the treatment of genotype 1 chronic hepatitis C 1, 5 http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-cc- cirrhosis-policy-statmmt-O615.pdf. NICE TA253 1.5.2 Budesonide Orodispersible 1 Epilepsy in Children SCG As opioid substitution therapy. https://www.shsc.nhs.uk/services/opiates-service- sheffield-treatment-and-recovery-team As opioid substitution therapy. https://www.shsc.nhs.uk/services/opiates-service-				in Amber section for monotherapy.	
Berotralistit 1,5 NHSE commissioned. NICE TA738 12.4 Beta Interferon 1,5 Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medication of a lipid clinic specialist. 2.12 Bezafibrate 1, 2 Hormonal Management of Prostatic Cancer SCP NICE TA738 8.3.4.2 Bicalutamide 1, 2 Hormonal Management of Prostatic Cancer SCP NICE TA253 6.3.3.2 Boceprevir for the treatment of genotype 1 chronic hepatitis C 1, 5 Intro/www.england.nhs.uk/cormissioning/wp-content/uploads/sites/12/2015/06/hep-c- NICE TA253 13.6.3 Brinonidine tartrate (Mirvaso®) 1 For management of rosacea: See Drug Safety Alerts on risk of exacerbation of rosacea See MHRA uodi systemic. Cardio/vascular e 4.8.1 Brivaracetam 1 Epilepsy in Children SCG Interps//www.shsc.nhs.uk/services/opiates-service: sheffield/treatment-and-recovery-team Interps//www.shsc.nhs.uk/services/opiates-service: sheffield/treatment-and-recovery-team 5.1 Buperoprophine prol					disease in adults.
Beta Interferon 1, 5 Becarotene 1, 5 Becarotene 1, 5 Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medication, in line with Prist Alert. Exceptions include oral anti cancer medication, in line with Prist Alert. Exceptions include oral anti cancer medication, in line with Prist Alert. Exceptions include oral anti cancer medication, in line with Prist Alert. Exceptions include oral anti cancer medication, in line with Prist Alert. Exceptions include oral anti cancer medication, in line with Prist Alert. Exceptions include oral anti cancer medication, in line with Prist Alert. Exceptions include oral anti cancer medication, in line with Prist Alert. Exceptions include oral anti cancer medication, in line with Prist Alert. Exceptions include oral anti cancer medication, in line with Prist Alert. Exceptions include oral anti cancer medication, in line with Prist Alert. Exceptions include oral anti cancer medication, in line with Prist Alert. Exceptions include oral anti cancer medication, in line with Prist Alert. Exceptions include oral anti cancer medication, in line with Prist Alert. Exceptions include oral anti cancer medication, in line with Prist Alert. Exceptions include oral anti cancer medication, in line with Prist Alert. Exceptions include oral anti cancer medication, in line with Prist Alert. Exceptions include oral anti cancer medication in line with Prist Alert. Exceptions include oral anti cancer medication in line with Prist Alert. Exceptions include oral anti cancer medication. In line with Prist Alert. Exceptions include oral anti cancer medication. In line with Prist Alert. Exceptions include oral anti cancer medication. In line with Prist Alert. Exceptions include oral anti cancer medication. In line with Prist Alert. Exceptions incl	4.2.1	•	,		
Bexarotene Arrow Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alerf. Exceptions include oral anti cancer medications where a shared care protocol exists. 2.12 Bezafibrate 1, 5 Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alerf. Exceptions include oral anti cancer medicines where a shared care protocol exists. 2.12 Bezafibrate 1 Patients would usually be on the initiation or recommendation of a lipid clinic specialist. 8.3.4.2 Bicalutamide 1, 2 Hormonal Management of Prostatic Cancer SCP NICE TA253 6.3.3.2 Boceprevir for the treatment of genotype 1 chronic hepatitis C 1, 5 http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-c- NICE TA253 13.6.3 Brimonidine tartrate (Mirvaso®) 1 For management of rosacea: See Drug Safety Alerts on risk of exacerbation of rosacea See MHRA updi systemic. cardiovascular e cardiovascular e befield/treatment-and-recovery-team 4.8.1 Brivaracetam 1 Epilepsy in Children SCG is 4.10.3 Buprenorphine 1, 5 sheffield/treatment-and-recovery-team so poind substitution therapy. https://www.shsc.nhs.uk/services/opiates-service-service-service-service-service-service-service-service-service-service-service-service-service-service-service-service-service-service-cardiovascular e commissioned Stop Smok	9 0 <i>4</i>		/ -	INHSE commissioned.	NICE TA738
5.1 1, 5 NPSA Alert. Exceptions include oral anti cancer medicines where a shared care protocol exists. 2.12 Bezafibrate 1 For hypertrig/yceridemia and/or mixed dyslipidaemia; however, use in this cohort of patients would usually be on the initiation or recommendation of a lipid clinic specialist. 8.3.4.2 Bicalutamide 1, 2 Hormonal Management of Prostatic Cancer SCP NICE TA253 6.3.3.2 Boceprevir for the treatment of genotype 1 chronic hepatitis C 1, 5 http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-c: cardiovascular extrate (Mirvaso®) NICE TA253 13.6.3 Brimonidine tartrate (Mirvaso®) 1 For management of rosacea: See Drug Safety Alerts on risk of exacerbation of rosacea See MHRA upd: systemic. cardiovascular extratores of the systemic system is and/row system is solid substitution therapy. https://www.shsc.nhs.uk/services/opiates-service-sheffield-treatment-and-recovery-team 1 4.10.3 Buprenorphine 1, 5 As opioid substitution therapy. https://www.shsc.nhs.uk/services/opiates-service-sheffield-treatment-and-recovery-team 1 4.10.2 Bupropion Hydrochloride 5 Clients over 12 years and non-pregnant women should be signposted to the commissioned Stop Smoking service http://sheffield.yorksiresmokefree.nhs.uk/ 8.1 Busulfan 1, 5 Should not be prescribed in primary care as an oral anticancer medication, in line with	0.2.4		1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with	
Protocol exists. Protocol exists. 2.12 Bezafibrate 1 For hypertriglyceridemia and/or mixed dyslipidaemia; however, use in this cohort of patients would usually be on the initiation or recommendation of a lipid clinic specialist. 8.3.4.2 Bicalutamide 1, 2 Hormonal Management of Prostatic Cancer SCP NICE TA253 6.3.3.2 Boceprevir for the treatment of genotype 1 chronic hepatitis C 1, 5 http://www.england.nbs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-c- NICE TA253 13.6.3 Brimonidine tartrate (Mirvaso®) 1 For management of rosacea: See Drug Safety Alerts on risk of exacerbation of rosacea See MHRA updi systemic. cardiovascular 6 4.8.1 Brivaracetam 1 Epilepsy in Children SCG NICE TA253 4.10.3 Buprenorphine 1, 5 sheffield-treatment-and-recovery-team sheffield-treatment-and-recovery-team 4.10.2 Buyropion Hydrochloride 5 Clients over 12 years and non-pregnant women should be signposted to the commissioned Stop Smoking service http://sheffield.vorkshiresmokefree.nhs.uk/ 8.1 NICE TA315 Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA.Alert. Exceptions include oral anti cancer medication, in line with Protocol exists.	8.1	Dexalotene	15		
2.12 Bezafibrate 1 For hypertriglyceridemia and/or mixed dyslipidaemia; however, use in this cohort of patients would usually be on the initiation or recommendation of a lipid clinic specialist. 8.3.4.2 Bicalutamide 1, 2 Hormonal Management of Prostatic Cancer SCP 5.3.3.2 Boceprevir for the treatment of genotype 1 chronic hepatitis C 1, 5 http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-c- cirrhosis-poloy-statmnt-0615.pdf. NICE TA253 13.6.3 Brimonidine tartrate (Mirvaso®) 1 For management of rosacea: See Drug Safety Alerts on risk of exacerbation of rosacea See MHRA upda systemic, cardiovascular e systemic, card	0.1		1, 5		
2.12 1 patients would usually be on the initiation or recommendation of a lipid clinic specialist. 8.3.4.2 Bicalutamide 1, 2 Hormonal Management of Prostatic Cancer SCP 5.3.3.2 Boceprevir for the treatment of genotype 1 chronic hepatitis C 1, 5 http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-c- cirrhosis-polcy-statmnt-0615.pdf. NICE TA253 13.6.3 Brimonidine tartrate (Mirvaso®) 1 For management of rosacea: See Drug Safety Alerts on risk of exacerbation of rosacea See MHRA updr systemic. 4.8.1 Brivaracetam 1 Epilepsy in Children SCG a 4.10.3 Buprenorphine 1, 5 As opioid substitution therapy. https://www.shsc.nhs.uk/services/opiates-service- sheffield-treatment-and-recovery-team a 4.10.2 Bupropion Hydrochloride 5 Clients over 12 years and non-pregnant women should be signposted to the commissioned Stop Smoking service http://sheffield.vorkshiresmokefree.nhs.uk/ shade or an an anticancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medication where a shared care protocol exists.		Bezafibrate			
8.3.4.2 Bicalutamide 1, 2 Hormonal Management of Prostatic Cancer SCP 5.3.3.2 Boceprevir for the treatment of genotype 1 chronic hepatitis C 1, 5 http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-cr- cirrhosis-polcy-statumt-0615.pdf. NICE TA253 13.6.3 Brimonidine tartrate (Mirvaso®) 1 For management of rosacea: See Drug Safety Alerts on risk of exacerbation of rosacea See MHRA upds systemic cardiovascular end to the provide the	2.12		1		
5.3.3.2 Boceprevir for the treatment of genotype 1 chronic hepatitis C 1, 5 http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-c-cirrhosis-polcy-statmnt-0615.pdf. NICE TA253 13.6.3 Brimonidine tartrate (Mirvaso®) 1 For management of rosacea: See Drug Safety Alerts on risk of exacerbation of rosacea See MHRA upda systemic cardiovascular endities/systemic cardiovascular endities/					
Boceprevir for the treatment of genotype 1 chronic hepatitis C 1, 5 cirrhosis-polcy-statmnt-0615.pdf. cirrhosis-polcy-statmnt-0615.pdf. 13.6.3 Brimonidine tartrate (Mirvaso®) 1 For management of rosacea: See Drug Safety Alerts on risk of exacerbation of rosacea MHRA See MHRA upda systemic. cardiovascular e 4.8.1 Brivaracetam 1 Epilepsy in Children SCG cardiovascular e 1.0.3 Buprenorphine 1, 5 As opioid substitution therapy. https://www.shsc.nhs.uk/services/opiates-service- sheffield-treatment-and-recovery-team ittps://www.shsc.nhs.uk/services/opiates-service- sheffield-treatment-and-recovery-team 4.10.2 Buprenorphine prolonged-release injection (Buvidal®) 1, 5 Clients over 12 years and non-pregnant women should be signposted to the commissioned Stop Smoking service http://sheffield.yorkshiresmokefree.nhs.uk/ 8.1 Busulfan 1, 5 NPSA Alert. Exceptions include oral anti cancer medication, in line with nrotcol exists. 6.1.2.3 Canagliflozin order sites. NICE TA315	8.3.4.2	Bicalutamide	1, 2		
Boceprevir for the treatment of genotype 1 chronic nepatitis C Chronic nepa	5.3.3.2		1.5		NICE TA253
13.6.3 1 MHRA systemic. cardiovascular et 4.8.1 Brivaracetam 1 Epilepsy in Children SCG cardiovascular et 1.5.2 Budesonide Orodispersible 1 As opioid substitution therapy. https://www.shsc.nhs.uk/services/opiates-service- 4.10.3 Buprenorphine prolonged-release injection (Buvidal®) 1, 5 As opioid substitution therapy. https://www.shsc.nhs.uk/services/opiates-service- 4.10.3 Buprenorphine prolonged-release injection (Buvidal®) 1, 5 As opioid substitution therapy. <a "="" href="https://www.shsc.nhs.uk/services/opiates-service-commissioned Stop Smoking service http://sheffield.yorkshiresmokefree.nhs.uk/ 4.10.2 Busulfan 5 Clients over 12 years and non-pregnant women should be signposted to the commissioned Stop Smoking service http://sheffield.yorkshiresmokefree.nhs.uk/ 8.1 Busulfan 1, 5 Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medication, in line with Protocol exists. NICE TA315 6.1.2.3 Canagliflozin NICE TA315	0101012		., •		
4.8.1 Brivaracetam 1 Epilepsy in Children SCG cardiovascular e 1.5.2 Budesonide Orodispersible 1 4.10.3 Buprenorphine 1, 5 As opioid substitution therapy. https://www.shsc.nhs.uk/services/opiates-service-sheffield-treatment-and-recovery-team 4.10.3 Buprenorphine prolonged-release injection (Buvidal®) 1, 5 As opioid substitution therapy. https://www.shsc.nhs.uk/services/opiates-service-sheffield-treatment-and-recovery-team 4.10.3 Buprenorphine prolonged-release injection (Buvidal®) 1, 5 Clients over 12 years and non-pregnant women should be signposted to the commissioned Stop Smoking service http://sheffield.yorkshiresmokefree.nhs.uk/ 8.1 Busulfan 1, 5 Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medication, in line with NICE TA315 6.1.2.3 Canagliflozin MICE TA315	40.0.0	Brimonidine tartrate (Mirvaso®)			
4.8.1 Brivaracetam 1 Epilepsy in Children SCG 1.5.2 Budesonide Orodispersible 1 4.10.3 Buprenorphine 1,5 4.10.3 Buprenorphine prolonged-release injection (Buvidal®) 1,5 4.10.2 Bupropion Hydrochloride 5 6.1.2.3 Canagliflozin Canagliflozin	13.6.3		1	MHRA	
1.5.2 Budesonide Orodispersible 1 Image: constraint of the properties of the pro	481	Brivaracetam	1	Enilensy in Children SCG	
4.10.3 Buprenorphine 1, 5 As opioid substitution therapy. https://www.shsc.nhs.uk/services/opiates-service-sheffield-treatment-and-recovery-team 4.10.3 Buprenorphine prolonged-release injection (Buvidal®) 1, 5 Image: Sheffield-treatment-and-recovery-team Image: Sheffield-treatme			•		
4.10.3 Buprenorphine prolonged-release injection (Buvidal®) 1, 5 sheffield-treatment-and-recovery-team 4.10.3 Bupropion Hydrochloride 1, 5 Clients over 12 years and non-pregnant women should be signposted to the commissioned Stop Smoking service http://sheffield.yorkshiresmokefree.nhs.uk/ 1 8.1 Busulfan 1, 5 Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medicates where a shared care protocol exists. 6.1.2.3 Canagliflozin NICE TA315			•	As opioid substitution therapy. https://www.shsc.nhs.uk/services/opiates-service-	
4.10.2 Bupropion Hydrochloride 5 Clients over 12 years and non-pregnant women should be signposted to the commissioned Stop Smoking service http://sheffield.yorkshiresmokefree.nhs.uk/ 8.1 Busulfan 1, 5 Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medicines where a shared care protocol exists. 6.1.2.3 Canagliflozin NICE TA315	4.10.3		1, 5	sheffield-treatment-and-recovery-team	
4.10.2 5 commissioned Stop Smoking service http://sheffield.yorkshiresmokefree.nhs.uk/ 8.1 Busulfan 1,5 Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medicines where a shared care protocol exists. 6.1.2.3 Canagliflozin Image: Commissioned Stop Smoking service http://sheffield.yorkshiresmokefree.nhs.uk/	4.10.3		1, 5		
8.1 Busulfan 1,5 Should not be prescribed in primary care as an oral anticancer medication, in line with protocol exists. 6.1.2.3 Canagliflozin NICE TA315	4.10.2	Bupropion Hydrochloride	5		
8.1 1, 5 NPSA Alert. Exceptions include oral anti cancer medicines where a shared care protocol exists. 6.1.2.3 Canagliflozin NICE TA315	4.10.2		Ŭ	commissioned Stop Smoking service http://sheffield.yorkshiresmokefree.nhs.uk/	
6.1.2.3 Canagliflozin protocol exists.		Busulfan			
6.1.2.3 Canagliflozin NICE TA315	8.1		1, 5		
	6122	Concelification			
	0.1.2.3			NICE TA614 with clobazam for seizures associated with Dravet Syndrome in people	
4.8 1,5 aged 2 years and older. See also related red entry for cannabidiol for Lennox Gastaut	4.8	Cannabidioi (Epidyolex~)			
syndrome and black section for Cannabis-based medicinal products.			., •		
Cannabidiol (Epidyolex®) NICE TA615 with clobazam for seizures associated with Lennox–Gastaut syndrome in NICE TA615		Cannabidiol (Epidvolex®)			NICE TA615
4.8 1, 5 people aged 2 years and older. See also related red entry for cannabidiol in Dravet	4.8		1, 5		
syndrome and black section for Cannabis-based medicinal products.			-,-		

10.2.2	Connahia, based medicinal unadusta	3	Black for all indications with the exception of those recommended in NICE NG144.	NICE NG144
10.2.2	Cannabis- based medicinal products	3	See related entries in red section for: Cannabis extract - Delta-9-tetrahydrocannabinol &	
			Cannabidiol (Sativex®) for spasticity in MS; Cannabidiol (Epidyolex®) for seizures	
			associated with Dravet Syndrome & Lennox- Gastaut syndrome; and Nabilone for	
			intractable nausea & vomiting.	
10.2.2	Cannabis extract - Delta-9-tetrahydrocannabinol &	1, 5	For spasticity in MS; as in line with NICE NG144. See also related entry under Cannabis	- <u>NG144</u>
10.2.2	Cannabidiol (Sativex®)	., •	based medicinal products in black section.	
	Capecitabine		Should not be prescribed in primary care as an oral anticancer medication, in line with	
8.1		1, 5	NPSA Alert. Exceptions include oral anti cancer medicines where a shared care	
			protocol exists.	
10.1.3	Certolizumab Pegol	1, 5		
	Chlorambucil		Should not be prescribed in primary care as an oral anticancer medication, in line with	
8.1		1, 5	NPSA Alert. Exceptions include oral anti cancer medicines where a shared care	
		, -	protocol exists.	
4.2.1	Chlorpromazine hydrochloride	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
	Ciclosporin	· · ·	Unless disease specific shared care arrangement in place. Regular monitoring required.	
8.2.2		1	See: Common blood monitoring	
11.4.2	Ciclosporin eye drops	1		NICE TA369
			To be prescribed by renal services, specialised commissioning. See Amber for primary	NICE TASOS
9.5.1.2	Cinacalcet	1, 5		
			hyperparathyroidism.	
9.5.1.2	Cinacalcet	1, 2, 3	Cinacalcet for Primary Hyperparathyroidism in Adults. See Red for prescribing by renal	
		-,_,-	services.	
	Clozapine		Patients must be registered with the appropriate clozapine monitoring service.	
4.2.1		1	Prescribing physicians must also register themselves and a nominated pharmacist with	
			the monitoring service.	
4.7.1	Co-codamol 8/500mg for acute pain in adults	4	See <u>Sheffield STOP list</u> for full details and note circumstances where prescribing may	
	· ·		be appropriate.	
	Cod Liver Oil	4		
	Co-enzyme Q10	1.4	For Friedreich's ataxia only; see Co-enzyme Q10 in black section.	
	Co-enzyme Q10	3	For all indications except Friedreich's ataxia; See Co-enzyme Q10 in red section.	
	······································	-	,	
	Colistimethate sodium (colistin sulfomethate sodium)		Specialised commissioning. To be prescribed by cystic fibrosis services. See also	
5.1.7		5	Amber section for non-cystic fibrosis bronchiectasis indication.	
	Colistimethate sodium (colistin sulfomethate sodium)		For non-cystic fibrosis bronchiectasis. Prescribe as Colomycin® brand. <u>See SCG.</u> See	
5.1.7	(Colomycin®)	1, 2, 3	Red section for cystic fibrosis.	
OTC Droporations		4	See <u>Sheffield STOP list</u> for full details and note circumstances where prescribing may	
OTC Preparations	Cough and cold remedies	4		
	O sele u h e se h e se i de		be appropriate.	
	Cyclophosphamide		Should not be prescribed in primary care as an oral anticancer medication, in line with	
8.1		1, 5	NPSA Alert. Exceptions include oral anti cancer medicines where a shared care	
			protocol exists.	
8.3.4.2	Cyproterone acetate	1, 2	Hormonal Management of Prostatic Cancer SCP	
	Dabigatran etexilate - for the prevention of venous	1, 5	See Amber and Green sections for other indications.	NICE TA157
2.8.2	thromboembolism after hip or knee replacement surgery in			
	adults. Note: full course to be provided by secondary care.			
0.0.0	Dabigatran etexilate - for the treatment and secondary	1	See Red and Green sections for other indications.	NICE TA327
2.8.2	prevention of deep vein thrombosis and/or pulmonary embolism	-		
	Dabigatran etexilate for preventing stroke and systemic		Local guidelines for the prevention of stroke in non-valvular atrial fibrillation. See Red	NICE TA249
2.8.2	embolism in people with non-valvular atrial fibrillation		and Amber sections for other indications.	
2.8.1	Dalteparin	1	Unless guidance available.	
2.0.1	Daitepaini			1

2.8.1	Dalteparin	1, 2, 3	Dalteparin SCG	
	Danazol		For unlicensed indications and more details, see CAS Supply Disruption Alert (29 May	
.7.2		1, 2, 3	2020): Note to prescribers: as there can be a delay in obtaining supplies; please allow 2	
			weeks for commumnity pharmacy to source the unlicensed product.	
0.2.2	Dantrolene sodium	1, 2, 3		
-	Dapagliflozin	, , -	Dapagliflozin for treating chronic heart failure with reduced ejection fraction (HFrEF).	NICE TA679
			Refer to primary care guidance. See also dapagliflozin: for treating chronic heart failure	
.1.2.3		1, 2, 3	with preserved or mildly reduced ejection fraction in line with NICE TA902, in amber	
		., _, •	section; for treating type 2 diabetes in line with NICE NG28, in Green section; and for	
			treating chronic kidney disease in line with NICE TA775, in Green section.	
	Dapagliflozin		Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF). Approved as AMBER-G by SY IMOC Jul 23.	NICE TA902
			See also dependification for treating chronic heart foilure with reduced ejection fraction in	
.1.2.3		1,2 (IMOC)	line with NICE TA679, in amber section; for treating type 2 diabetes in line with NICE	
			NG28, in Green section; and for treating chronic kidney disease in line with NICE	
			TA775. in Green section.	
	Dapagliflozin		Dapagliflozin for treating type 2 diabetes.	NICE NG28
	Dapaginiozin			
			See also dapaglifozin: for treating chronic kidney disease in line with NICE TA775 in	
.1.2.3			Green section; for treating heart failure with reduced ejection fraction, in line with NICE	
			TA679, in Amber section; and for treating heart failure with reduced ejection nacion, in fine with reduced	
			ejection fraction, in line with NICE TA902 in Amber section.	
	Dapagliflozin	-	Dapagliflozin for treating chronic kidney disease. Refer to CKD primary care guideline to	
	Dapagimozin		support prescribing.	NICE TATTS
			Support presentating.	
.1.2.3			See also dapagliflozin: for treating type 2 diabetes in line with NICE NG28, in Green	
.1.2.3			section; for treating heart failure with reduced ejection fraction, in line with NICE TA679,	
			in Amber section; and for treating heart failure with preserved or mildly reduced ejection	
			fraction, in line with NICE TA902 in Amber section.	
	Dan susting			
.4.6	Dapoxetine	1, 2	To be prescribed only when all the criteria specified in the <u>SPC</u> are met. A maximum	
1.0			supply of 6 tabs per month is advised by the Sheffield APG.	
.1.3	Darbepoetin alfa	1, 5	Renal Anaemia, specialised commissioning.	
3.4.2	Degarelix	1, 2	Hormonal Management of Prostatic Cancer SCP	
3.1	Didanosine	1, 5	NHSE commissioned.	
.2.4	Dimethyl fumarate (Skilarence®)	1, 5	For moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy. NICE TA 475	
.2.4	Dimethyl fumarate (Tecfidera®)	1, 5	NICE TA320	
.10.1	Disulfiram	1, 2	Alcohol Relapse Prevention Guideline	
.3.1	Dolutegravir (including combinations)	1, 5	NHSE commissioned.	
.11	Donepezil	1, 2, 3	Dementia SCG	
.7	Dornase Alfa	5	Specialised commissioning. To be prescribed by cystic fibrosis services.	
.1.2.3		1		
	Edoxaban for preventing stroke and systemic embolism in		Local guidelines for the prevention of stroke in non-valvular atrial fibrillation. See Amber	NICE TA355
.8.2	people with non-valvular atrial fibrillation		section for other indication.	
	Edoxaban for the treatment and secondary prevention of deep	1	Note: treatment of DVT and PE will be initiated in secondary care. See Green section for	NICE TA354
.8.2	vein thrombosis and pulmonary embolism	· ·	other indication.	
.3.1	Efavirenz (including combinations)	1, 5	NHSE commissioned.	
		,		
.3.3	Elbasvir with grazoprevir (Zepatier)	1, 5	NHSE commissioned.	NICE TA413

	Electronic Cigarettes	4	Self-care should be encouraged and patients can be referred to the stop smoking service.	
5.3.1	Elvitegravir (including combinations)	1, 5	NHSE commissioned.	
	Empagliflozin	1,2,3	Empagliflozin for treating chronic heart failure with reduced ejection fraction (HFrEF).	
6.1.2.3		.,_,•	Refer to primary care guidance. See also empagliflozin: for treating chronic heart failure	
0111210			with preserved or mildly reduced ejection fraction in line with NICE TA929	NICE TA773
	Empagliflozin	1,2 (IMOC)		
	Linpaginiozin	1,2 (11100)	Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection	
6.1.2.3			fraction (HFpEF). Approved as AMBER-G by SY IMOC Dec 23. See also empagliflozin:	
			for treating chronic heart failure with reduced ejection fraction in line with NIC	NICE TA929
	Empagliflozin		Empagliflozin for treating type 2 diabetes. See	
	Empagnitozin		also empaglifozin: for treating chronic kidney disease in line with NICE TA942 in Green	
6.1.2.3			section; for treating heart failure with reduced ejection fraction, in line with NICE TA773,	
0.1.2.0			in Amber section; and for treating heart failure with preserved or mildly reduced ejection	
			fraction, in line with NICE TA929 in Amber section.	NICE NG28
	Empagliflozin	+	Empagliflozin for treating chronic kidney disease. Approved as GREEN by SY IMOC	
	Empayimozin	1	Feb 24.	
		1	See also empaglifozin: for treating type 2 diabetes in line with NICE NG28, in Green	
6.1.2.3			section; for treating heart failure with reduced ejection fraction, in line with NICE TA773,	
			in Amber section; and for treating heart failure with preserved or mildly reduced ejection	
F 0 4		4.5	fraction, in line with NICE TA929 in Amber section.	NICE TA942
5.3.1	Emtircitabine (including combinations)	1, 5	NHSE commissioned.	
5.3.1	Enfuvirtide	1, 5	NHSE commissioned.	
2.8.1	Enoxaparin	1	Unless guidance available.	
5.3.3	Entecavir	1, 5	NHSE commissioned. <u>NICE CG165</u>	NICE TA153
9.4.2	Enteral Feeding Solutions	1	When dietetic advice is provided. See appendix 2 of the BNF for full list.	
2.5.5.2	Entresto® (sacubitril valsartan)	1, 2, 3	ONLY to be transferred to a GP when patient has been up titrated and on a stable,	NICE TA388
			optimal dose.	
2.2.3	Eplerenone	1	For patients intolerant of spironolactone due to gynaecomastia.	
9.1.3	Epoetin alfa, beta & zeta	1, 5	Renal Anaemia, specialised commissioning.	
	Estramustine phosphate		Should not be prescribed in primary care as an oral anticancer medication, in line with	
8.1		1, 5	NPSA Alert. Exceptions include oral anti cancer medicines where a shared care	
			protocol exists.	
7.3.1	Ethinylestradiol with Etonogestrel vaginal ring (NuvaRing®)	1		
4.8.1	Ethosuximide	1	Epilepsy in Children SCG	NICE CG137
	Etoposide		Should not be prescribed in primary care as an oral anticancer medication, in line with	
8.1		1, 5	NPSA Alert. Exceptions include oral anti cancer medicines where a shared care	
		, -	protocol exists.	
5.3.1	Etravirine	1, 5	NHSE commissioned.	
2.12	Evolocumab	1		NICE TA394
	Exemestane	† •	Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on	
8.3.4.1		1, 2	prescribing for a specified duration, for advice on drug management see: <u>Referral and</u>	
0.0.4.1		1, 2	Management Guidelines for Breast Cancer. See also, section on ibandronic acid.	
6.1.2.3	Exenatide	1		
10.1.4	Febuxostat		Now first line with allopurinol.	NICE NG219
10.1.4		1.5	NHSE commissioned.	
	Fenfluramine	т, э		NICE TA808

			The base of the state of the st	
0.40	Fenofibrate		For hypertriglyceridemia and/or mixed dyslipidaemia; however, use in this cohort of	
2.12		1	patients would usually be on the initiation or recommendation of a lipid clinic specialist.	
	Fidaxomicin		If prescribed in line with NICE NG199 as a second line antibiotic for a first episode of	NICE NG199
			mild, moderate or severe C.difficile infection if vancomycin ineffective or for a further	
5.1.7		1	episode (see NICE guidance). Following specialist recommendation, fidaxomicin may be	•
			prescribed by a primary care clinician. See also vancomycin (oral) in Green section.	
10.1.3	Filgotinib	1, 5		NICE TA676
10.1.3	Filgotinib	1, 5		NICE TA792
8.2.4	Fingolimod	1		NICE TA254
13.8.1	Fluorouracil (5-Fluorouracil) cream 5% (Efudix®)		See: Actinic keratosis pathway	
4.2.1	Flupentixol	1.2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
5.3.1		1, 2	NHSE commissioned.	
0.0.1	Fosamprenavir			NICE TA759
	Fostamatinib	1, 5		NICE TA759
	Fulvestrant		Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on	
8.3.4.1		1, 2	prescribing for a specified duration, for advice on drug management see: <u>Referral and</u>	
			Management Guidelines for Breast Cancer. See also, section on ibandronic acid.	
4.11	Galantamine	1, 2, 3	Dementia SCG	
4.7.4	Galcanezumab	1, 5		NICE TA659
	gammaCore	1		MTG 46
8.2.4	Glatiramer	1, 5	NHSE commissioned.	
5.3.3	Glecaprevir with pibrentasvir (Maviret®)	1, 5	NHSE commissioned.	NICE TA499
	Goserelin	· · ·	Hormonal Management of Prostatic Cancer SCP. NB see also goserelin in endocrine	
8.3.4.2		1, 2	management of breast cancer.	
	Goserelin		Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on	
	Goserenn		prescribing for a specified duration, for advice on drug management see: <u>Referral and</u>	
8.3.4.1		1, 2	prescribing for a specified duration, for advice of drug management see. <u>Referral and</u>	
			Management Guidelines for Breast Cancer. See also, section on ibandronic acid. See	
			also goserelin in the management of prostatic cancer.	
4.4	Guanfacine	1, 2, 3	Shared Care for the Management of Prescribing for ADHD	
4.2.1	Haloperidol	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
OTC Preparation	s Hayfever preparations (OTC antihistamines)	4	See <u>Sheffield STOP list</u> for full details and note circumstances where prescribing may	
			be appropriate.	
	Hydroxycarbamide		Red for all indications. In certain circumstances, in the patient's best interests, the blood	
045		4.5	monitoring may be undertaken by the GP at the request of the haematology specialist.	
8.1.5		1, 5	The specialist will provide details of the tests required following each out-patient	
			appointment.	
10.1.3	Hydroxychloroquine	1, 2, 3	Hydroxychloroquine Prescribing in Adults SCG	
	Ibandronic acid	., _, J	Prescribing Guideline - Ibandronic acid in post menopausal women with breast cancer-	See also Referral and
6.6.2		1, 2	unlicensed indication. Note, use only ibandronic 50mg tablets.	Management of
0.0.2		1, 2	מווויטרושט וויטוטמווטוו. ויוטוב, עשב טוווץ ושמווטוטווט שטוווץ נמטובנג.	Breast Cancer.
		-	See Sheffield STOP list for full details and note circumstances where prescribing may	breast Cancer.
OTC Preparation	s Ibuprofen 200mg - 400mg for acute pain in adults	4		
			be appropriate.	
2.12	Icosapent ethyl	1		NICE TA805
	Idarubicin		Should not be prescribed in primary care as an oral anticancer medication, in line with	
8.1		1, 5	NPSA Alert. Exceptions include oral anti cancer medicines where a shared care	
			protocol exists.	
2.5.1	lloprost	1, 5	Patients treated for Pulmonary Arterial Hypertension.	
13.7	Imiguimod	1		

2.12	Inclisiran		For secondary prevention of cardiovascular disease in line with NICE TA733 - further guidance on implementation to follow.	NICE TA733
10.1.3	Infliximab	1, 5		
Respiratory	Inspiratory Muscle Trainer (IMT) Device. e.g. Powerbreathe	4	See IMT prescribing guidance	
devices	Medic, Phillips Threshold IMT.	1	See <u>INT prescribing guidance</u>	
6.1.1.1	Insulin aspart (Fiasp®)	1	For children only, as identified by the secondary care specialist. The first prescription can, with agreement of the primary care clinician, be issued in primary care, subject to	
0.1.1.1		ľ	receiving a detailed communication, from the specialist, which includes information on the ongoing support and monitoring that secondary care will provide.	
6.1.2	Insulin degludec	1, 2, 3	For use in restricted patient populations. Please take care with the strength of insulin degludec, see: <u>MHRA guidance</u> . Also see amber section for Xultophy®.	
6.1.1	Insulin glargine 300u/ml injection (Toujeo®)		Please prescribe by brand and take care with the strength of insulin.	See MHRA advice
13.6.2	Isotretinoin	1		
2.6.3	Ivabradine	1	TA267 - Ivabradine for treating chronic heart failure.	NICE CG126 Stable
		•		angina management
Prescribing in Palliative Care	Ketamine	1	To be prescribed by Palliative Care Team.	
5.3.1	Lamivudine (including combinations)	1, 5	NHSE commissioned.	
8.3.4.3	Lanreotide	1, 2, 3	Acromegaly SCP Specialist to initiate and stabilise dose.	
9.5.2.2	Lanthanum	1, 5	To be prescribed by renal services, specialised commissioning.	
5.3.3	Ledipasvir with sofosbuvir (Harvoni®)	1, 5	NHSE commissioned.	NICE TA363
10.1.3	Leflunomide	1, 2, 3	Leflunomide SCP	
8.2.4	Lenalidomide	1		
	Letrozole		Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on	
8.3.4.1		1, 2	prescribing for a specified duration, for advice on drug management see: <u>Referral and</u>	
			Management Guidelines for Breast Cancer. See also, section on ibandronic acid.	
8.3.4.2	Leuprorelin	1, 2	Hormonal Management of Prostatic Cancer SCP.	
	Lidocaine plasters		Approved by Sheffield Teaching Hospitals for post operative neuropathic pain of chest	NICE CG173
45.0	· ·		drain site (thoracic surgery). This is mainly inpatient use but possibly on discharge for	
15.2		1	short period of time. Not for continued prescribing. Also, see Black and Amber sections.	
15.2	Lidocaine plasters	1, 2, 3	In exceptional circumstances agreed with pain clinic or palliative care. See prescribing	NICE CG173
15.2	Lideocino plastara	4	guidance. Also, see Black and Red sections. See <u>Sheffield STOP list</u> for full details and note circumstances where prescribing may	NICE CG173
15.2	Lidocaine plasters	4	be appropriate. See also red and amber sections.	NICE CG173
1.6.7	Linaclotide		As a third line treatment for moderate to severe irritable bowel syndrome with constipation in adults. See local guidelines.	
5.1.7	Linezolid	1, 5	Refer relevant patients to the STHFT oral linezolid OPAT service	
4.5	Liraglutide (Saxenda®)	1	The pathway for managing overweight and obesity, in line with NICE TA664 via a specialist tier 3 weight management service, is still being explored and so liraglutide (Saxenda®) is currently not able to be prescribed by primary care prescribers nor is it	NICE TA664
			available through Live Lighter. If you have any patients who meet the criteria for use or have any queries, please e mail: <u>APG mailbox</u> . See also Black and Amber sections.	
4.5	Liraglutide (Saxenda®)	4	For use outside the NICE TA 664. See also Red and Amber sections.	
6.1.2	Liraglutide (Victoza®)	1	For Type 2 diabetes in adults:management. See also liraglutide (Victoza®) for children, in Amber section and liraglutide (Saxenda®) in Black and Red sections.	NICE NG28
6.1.2	Liraglutide (Victoza®) for children	1, 2	As third line management in children and young people aged 10 years and over. See also liraglutide / Saxenda in Black and Red sections.	
4.4	Lisdexamfetamine	1, 2, 3	Shared Care / Prescribing Guideline for the management for prescribing in ADHD	NICE TA98

4.2.3	Lithium carbonate	1, 2	Bipolar Disorder SCG	
6.1.2.3	Lixisenatide	1		
4.10.3	Lofexidine hydrochloride	1, 2	For the treatment of opioid dependence, If advice available from specialist services, and prescribed in accordance with national treatment guidelines – otherwise RED. Local guidelines available for GPs who agree to prescribe.	
8.1	Lomustine	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with <u>NPSA Alert.</u> Exceptions include oral anti cancer medicines where a shared care protocol exists.	
5.3.1	Lopinavir with Ritonavir	1, 5	NHSE commissioned.	
1.8.2	Lorazapam	1	Epilepsy in Adults SCP	NICE CG137
4.8.2	Lorazapam	1	Epilepsy in Children SCG	NICE CG137
9.1.4	Lusutrombopag	1, 5		NICE TA617
2.5.1	Macitentan	1, 5	Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned.	
5.3.1	Maraviroc	1, 5	NHSE commissioned.	
10.1.1	Mefenamic acid	4	Not approved for initiation in new patients diagnosed with dysmenorrhoea or menorrhagia.	
4.1.1	Melatonin	4	For unlicensed melatonin preparations, Colonis melatonin 3mg film coated tablets and Colonis melatonin 1mg/ml oral solution for jet lag in adults. Also see Amber and Green	
			sections of TLDL and the <u>Melatonin in treatment of Sleep Disorders in Children SCP.</u>	
4.1.1	Melatonin (Circadin 2mg MR tabs - in adults)		For licensed indication. Also see Black and Amber sections.	
4.1.1	Melatonin (Circadin® 2mg MR tabs and 5mg/5ml oral solution only - in children)	1, 2, 3	Melatonin in treatment of Sleep Disorders in Children SCG. Also see Black and Green sections.	
4.1.1	Melatonin (Slenyto® 1mg and 5mg MR tabs)	1, 2, 3	Amber for licensed indications, see <u>Melatonin in treatment of Sleep Disorders in</u> <u>Children SCG.</u> Also see Black and Green sections.	
4.11	Memantine	1, 2, 3	Dementia SCG	
8.1.3	Mercaptopurine	1, 2, 3	Should not be prescribed in primary care as an oral anticancer medication. Should only be prescribed for inflammatory bowel disease following agreement with a local specialist. Azathioprine and mercaptopurine SCP	
4.10.3	Methadone	1, 5	As opioid substitution therapy. <u>https://www.shsc.nhs.uk/services/opiates-service-sheffield-treatment-and-recovery-team</u>	
10.1.3	Methotrexate	1, 2, 3	Methotrexate SCG	
.1.3.	Methoxy polyethylene glycol - epoetin beta	1, 5	Renal Anaemia, specialised commissioning.	
Prescribing in Ventricular	Mexiletine	1, 4	Ventricular arrythmias - unlicensed indication not in BNF	
arrhythmias 2.3.2	Mexiletine (Namuscla®)	4.5	NHSE commissioned	NICE TA748
	Midodrine	1, 5	Midodrine SCP	
2.7.2	Midodrine	1, 2, 3	For use in those aged 18 years and over, in line with NICE TA 290 for treating the symptoms of overactive bladder only where antimuscarinic drugs are contraindicated or	NICE TA290
7.4.2			clinically ineffective, or have unacceptable side effects.	
8.1	Mitotane	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with <u>NPSA Alert.</u> Exceptions include oral anti cancer medicines where a shared care protocol exists.	
4.4	Modafinil	1, 5	For new patients prescribed modafinil for unlicensed indications, approved by Medicines Safety Committee, STHFT, as listed in the <u>Modafinil SCP</u> . See black section for other unlicensed indications and amber section for licensed use in narcolepsy.	

	Modafinil		Only for licensed use in narcolepsy Modafinil SCP (September 2013). See red section	
4.4	Modalilli	1, 2	for unlicensed indications approved by Medicines Safety Committee STHFT listed in the	
		., _	SCP, and black section for other unlicensed indications.	
4.4	Modafinil	3	For new patients prescribed modafinil for unlicensed indications other than those	
	Modulini	Ũ	approved by Medicines Safety Committee, STHFT (see red section). See amber section	
			for licensed use in narcolepsy.	
	Morphine orodispersible tablets (Actimorph®)		Morphine orodispersible tablets (Actimorph®) are an option for use in vulnerable patient	
4.7.2	······································		groups, to reduce the risk of accidental or intentional overdose; or where there are	
			dexterity issues.	
	Mycophenolate		Specialised commissioning; to be prescribed by specialist services for transplant	
8.2.1		1, 3	recipients. See also amber section for Adult rheumatology patients with connective	
			tissue disease.	
8.2.1	Mycophenolate	1, 2, 3	Mycophenolate Mofetil SCG. See Red section for transplant recipients.	
4.6	Nabilone	1, 5	For intractable nausea and vomiting.	NICE NG144
1.6.6	Naldemedine	1		NICE TA651
4.10.1	Nalmefene	1, 5	Sheffield Alcohol Service: https://shsc.nhs.uk/service/sheffield-alcohol-services/	NICE TA325
1.6.6	Naloxegol	1		NICE TA345
	Naltrexone hydrochloride		For the treatment of opioid dependence, If advice available from specialist services, and	
4.40.0		1.2	prescribed in accordance with national treatment guidelines – otherwise RED. Local	
4.10.3		1, ∠	guidelines available for GPs who agree to prescribe. For alcohol relapse prevention see	
			Green section.	
	Naltrexone hydrochloride		If initiated in primary care, to be prescribed by a GP/prescriber with special interest OR	
4.10.3			experience in alcohol relapse prevention and in conjunction with an offer of	
			psychological interventions. See the prescribing guideline for more information.	
5.3.1	Nevirapine	1, 5	NHSE commissioned.	
1.10.2	Nicotine	5	Clients over 12 years and non-pregnant women should be signposted to the	
		-	commissioned Stop Smoking service http://sheffield.yorkshiresmokefree.nhs.uk/	
14.5.1	Normal Immunoglobulin	1, 2	Home therapy booklet for GPs	
10.3.2	NSAIDs (topical) diclofenac sodium, felbinac, ibuprofen,		In line with NICE guidance for osteoarthritis. Topical ibuprofen is the Sheffield formulary	NICE NG226
	ketoprofen and piroxicam		choice. See also entry in Black section.	
10.3.2	NSAIDs (topical) diclofenac sodium, felbinac, ibuprofen,	4	For self-care. See also entry in Green section.	
Dresseribing in	ketoprofen and piroxicam			
Prescribing in primary biliary	Obeticholic acid	1, 5		NICE TA443
cholangitis		1, 5		
8.3.4.3	Octreotide	1, 2, 3	Acromegaly SCP Specialist to initiate and stabilise dose.	
4.2.2	Olanzapine (depot injection)	1, 2, 3	SHSC have stated that they would not be routinely initiating prescriptions.	
4.2.1	Olanzapine (depot injection) Olanzapine (oral medication only)	1, 2	Specialist to initiate and stabilise dose.	
4.2.1 2.12	Omega-3-Fatty Acid capsules (e.g.Omacor®, Prestylon®,		For hypertriglyceridaemia to prevent acute pancreatitis.	
2.12	Nebbaro® and Maxepa®)	1		
	Ondansetron		Not normally indicated for primary care use.	
4.6		1	For unlicensed use in palliative care, see palliative care formulary here	
Respiratory	Oscillating Positive Expiratory Pressure (OPEP) Device e.g.	4		
devices	Acapella®, Aerobika	1	See OPEP prescribing guidance	
4.7.2	Oxycodone and naloxone combination product (Targinact®)	4	See <u>Sheffield STOP list</u> for full details and note circumstances where prescribing may	
			be appropriate.	
4.2.1	Paliperidone	1	SHSC have stated that they would not be routinely initiating prescriptions.	

OTC Preparations	Paracetamol for acute pain in adults	4	See <u>Sheffield STOP list</u> for full details and note circumstances where prescribing may	
	•		be appropriate.	
9.2.1.1	Patiromer	1, 5		NICE TA623
8.1.5	Pazopanib	1, 5		NICE TA215
8.2.4	Peginterferon alfa	1, 5	NHSE commissioned. NICE CG165	NICE TA96
5.3.3.2	Peginterferon alfa with ribavirin for treating chronic hepatitis C in adults. See also in Red section for children and young people.	1, 5	NHSE commissioned.	NICE TA200
5.3.3.2	Peginterferon alfa with ribavirin for treating chronic hepatitis C in children and young people. See also in Red section for adults.	1, 5	http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-c- cirrhosis-polcy-statmnt-0615.pdf	NICE TA300
10.1.3	Penicillamine	1, 2	For the treatment of Wilsons Disease and Cystinuria in adults.	
2.8.1	Pentosan polysulfate sodium	1, 5		NICE TA610
4.9.1	Pergolide	1	Parkinson's Disease SCP	
4.2.1	Pericyazine	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
4.2.1	Perphenazine	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
13.5.3	Pimecrolimus (topical)		When a prescriber is GPwSI in dermatology, or on their recommendation, or is competent in prescribing in dermatological conditions	NICE TA82
4.2.1	Pimozide	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
4.2.1	Pipotiazine Palmitate	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
3.11	Pirfenidone	1, 5		NICE TA504
	Ponesimod	1, 5	NHSE commissioned.	NICE TA767
5.2.1	Posaconazole	1, 5	NHSE commissioned.	
2.9	Prasugrel	1		NICE TA317
OTC Preparations	Probiotics	4	See <u>Sheffield STOP list</u> for full details and note circumstances where prescribing may be appropriate.	
8.1	Procarbazine	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with <u>NPSA Alert.</u> Exceptions include oral anti cancer medicines where a shared care protocol exists.	
4.2.1	Prochlorperazine	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
4.2.1	Promazine hydrochloride	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
1.6.7	Prucalopride	1, 2	See <u>prescribing guidance</u> to support specialist initiation and ongoing prescribing in primary care.	
4.2.1	Quetiapine	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
4.2.1	Quetiapine modified release	1	SHSC have stated that they would not be routinely initiating prescriptions.	
5.3.1	Raltegravir	1, 5	NHSE commissioned.	
2.6.3	Ranolazine	1	Cardiologist initiation in line with NICE CG126.	NICE CG126
A 2.4.2 Vitamin and mineral supplements	Renavit®	1	Dietary management of water soluble vitamin deficiency in renal patients receiving dialysis.	
5.1.7	Rifaximin (Targaxan®)	1, 2, 3	For preventing episodes of overt hepatic encephalopathy. Rifaximin guideline	NICE TA337
5.3.1	Rilpivirine (including combinations)	1, 5	NHSE commissioned.	
2.5.1	Riociguat	1, 5	Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned.	
4.2.1	Risperidone	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
5.3.1	Ritonavir	1, 5	NHSE commissioned.	

	Rivaroxaban for preventing stroke and systemic embolism in		Local guidelines for the prevention of stroke in non-valvular atrial fibrillation. See Red	NICE TA256
2.8.2	people with non-valvular atrial fibrillation		and Amber sections for other indications.	
2.8.2	Rivaroxaban 2.5mg tablets for patients with coronary artery disease (CAD) or peripheral artery disease (PAD) at high risk of	1	See Red and Green sections for other indications.	NICE TA607
	ischaemic events.			
2.8.2	Rivaroxaban 2.5mg tablets for preventing adverse outcomes	1	See also local guidelines. Note: treatment will be initiated in secondary care. See Red	NICE TA335
2.0.2	after acute management of acute coronary syndrome		and Green sections for other indications.	
	Rivaroxaban for the treatment of deep vein thrombosis and	1	See Red and Green sections for other indications.	NICE TA261
2.8.2	prevention of recurrent deep vein thrombosis and pulmonary			
	embolism			
2.8.2	Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism	1	See Red and Green sections for other indications.	NICE TA287
	Rivaroxaban: Prophylaxis of venous thromboembolism following	1, 5	See Amber and Green sections for other indications.	NICE TA170
2.8.2	hip and knee replacement surgery. Note: full course to be			
	provided by secondary care.			
l.11	Rivastigmine	1, 2, 3	Dementia SCG	
3.3.3	Roflumilast	1		NICE TA461
6.2	Romosozumab	1, 5		NICE TA791
.1.3	Roxadustat	1, 5		NICE TA807
5.1.5	Ruxolitinib	2		NICE TA289
5.3.1	Saquinavir	1, 5	NHSE commissioned.	
Prescribing in PAH	Selexipag	1, 5	Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned.	
.1.2.3	Semaglutide (Ozempic®) and (Rybelsus®)	1		NICE NG28
).5.2.2	Sevelamer (Renagel®)	1, 5	To be prescribed by renal services, specialised commissioning.	
2.5.1	Sildenafil (For Pulmonary Arterial Hypertension)	1, 5	Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned. See also sildenafil entries for Erectile Dysfunction.	
	Sildenafil (prescribed as Viagra®) (For Erectile Dysfunction)		If SLS critearia not met a GP may provide a private prescription (detailed in HSC)	Prescribing of generic
7.4.5	ondenani (presented as viagrae) (i or Erectile Dystaliction)	1, 2	<u>1999/148</u>). See also entry in green section.	sildenafil
7.4.5	Sildenafil (Prescribed as Viagra®) (For Erectile Dysfunction)		SLS criteria applies - prescriptions may be issued for patients eligible for NHS treatment (as per SI 2004 No 629), otherwise RED. Note - Patients with Severe Distress are not covered by SLS criteria (as detailed in HSC 1999/177).	
	Sildenafil (Prescribed generically) (For Erectile Dysfunction)		SLS criteria does not apply for sildenafil prescribed generically (detailed in SI 2014 No.	Prescribing of generic
7.4.5	(1625). See also sildenafil prescribed as Viagra® in green and red sections.	sildenafil
5.3.3.2	Simeprevir in combination with peginterferon alfa and	1, 5	http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-c-	NICE TA331
0.0.0.2	ribavirin for treating genotypes 1 and 4 chronic hepatitis C.		cirrhosis-polcy-statmnt-0615.pdf	
.2.4	Siponimod	1, 5		NICE TA656
3.2.2	Sirolimus	1, 5	NHSE commissioned.	
l.1.1	Sodium Oxybate	1, 5		
4.1.1	Sodium Oxybate	3	In adults, not previously treated with sodium oxybate for narcolepsy with cataplexy. See	
	-		red section for children and for adults who have transitioned from children's to adult	
			services and have already been prescribed this drug for narcolepsy.	
.3.3.2		1, 5	http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-c-	NICE TA330
	Sofosbuvir for treating chronic hepatitis C		cirrhosis-polcy-statmnt-0615.pdf	
6.5.1	Somatropin (Adults)	1, 2	The treatment of Adults with Growth Hormone (Somatropin)SCG	
6.5.1	Somatropin (Children) Human growth hormone (somatropin) for the treatment of growth failure in children	1, 2	The treatment of Children with Recombinant Human Growth Hormone SCG	NICE TA188
5.2.4	Stavudine	1, 5	NHSE commissioned.	

6.6.2	Strontium Ranelate	1		
4.10.3	Suboxone®	1, 5	As opioid substitution therapy. https://www.shsc.nhs.uk/services/opiates-service-	
4.10.5		1, 5	sheffield-treatment-and-recovery-team	
	Sucralfate		Only on specialist advice for licenced and off-label indications, which include: in highly	
1.3.3		1	selected cases with severe refractory oesophageal ulceration with dysphagia and	
			bleeding and as a temporary measure to help with post banding bleeding in	
0.5.0			varices. Review after 8-12 weeks of continued use.	
9.5.2	Sucroferric oxyhydroxide	1, 5	NHSE commissioned.	NICE NG203
10.1.3	Sulfasalazine	1, 2, 3	Sulfasalazine SCG	
4.2.1	Sulpiride	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
8.2.2	Tacrolimus (oral)	1	See GREEN section for topical tacrolimus.	
	Tacrolimus (topical)		When a prescriber is GPwSI in dermatology, or on their recommendation, or is	NICE TA82
13.5.3			competent in prescribing in dermatological conditions. See also Red section for oral	
	Todolofil (For Frontile Duration)		tacrolimus. If SLS critearia not met a GP may provide a private prescription (detailed in HSC	
7.4.5	Tadalafil (For Erectile Dysfunction)	1, 2	1999/148). See also entries in green section and black section (once daily preparations)	
7.4.5		1, 2		
	Tadalafil (For Erectile Dysfunction)		SLS criteria applies - NHS FP10 prescriptions may be issued for patients who meet SLS	HSC 1999/177
			criteria (as per SI 2004 No 629), otherwise RED. Note - Patients with Severe Distress	
7.4.5			are not covered by SLS criteria (as detailed in HSC 1999/177). See also once daily	
			preparations in black section.	
0.5.4	Tadalafil (For Pulmonary Arterial Hypertension)	4 5	Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned. See also	
2.5.1		1, 5	tadalafil entries for Erectile Dysfunction.	
7.4.5	Tadalafil Once Daily 2.5mg/5mg (for Erectile Dysfunction)	4	See <u>Sheffield STOP list</u> for full details. See also entries in Red and Green sections.	
4.7.2	Tapentadol	3		
	Tegafur with gimeracil and oteracil		Should not be prescribed in primary care as an oral anticancer medication, in line with	
8.1		1, 5	NPSA Alert. Exceptions include oral anti cancer medicines where a shared care	
			protocol exists.	
	Temozolomide		Should not be prescribed in primary care as an oral anticancer medication, in line with	
8.1		1, 5	NPSA Alert. Exceptions include oral anti cancer medicines where a shared care	
5.0.4	Tanafavia Alafanamida (including combinations)	4.5	protocol exists. NHSE commissioned.	
5.3.1	Tenofovir Alafenamide (including combinations)	1, 5		
5.3.1	Tenofovir Disoproxil (including combinations)	1, 5	NHSE commissioned.	
8.2.4	Teriflunomide	1, 5	NHSE commissioned.	NICE TA303
6.4.2	Testosterone: topical preparations for post-menopausal	1, 2, 3	Topical testosterone replacement therapy in postmenopausal women SCP. See also	
	women		green section Only where primary care prescriber has knowledge and competency to initiate	NICE NG23 NICE NG23
6.4.2	Testosterone: topical preparations for post-menopausal		testosterone without referral to the menopause clinic. See also amber section and	INICE ING23
0.4.2	women		Topical testosterone replacement therapy in postmenopausal women SCP	
8.2.4	Thalidomide	1		
4.8.1	Tiagabine	1	Epilepsy in Children SCG	NICE CG137
	Ticagrelor	· ·	NICE TA420 for preventing atherothrombotic events after myocardial infarction.	NICE TA236 for the
2.9	i i ougi oi oi	1		treatment of acute
				coronary syndromes
2.8.1	Tinzaparin	1	Unless guidance available.	
	Tioguanine		Should not be prescribed in primary care as an oral anticancer medication, in line with	
8.1		1, 5	NPSA Alert. Exceptions include oral anti cancer medicines where a shared care	
			protocol exists.	

5.3.1	Tipranavir	1, 5	NHSE commissioned.	
10.2.2	Tizanidine	1, 2, 3	Specialist prescribing for first 4 months.	
	Tobramycin		Specialised commissioning. To be prescribed by cystic fibrosis services. See also	
5.1.4		5	Amber section for non-cystic fibrosis bronchiectasis indication.	
3.7	Tobramycin	1, 2, 3	For non-cystic fibrosis bronchiectasis; see <u>SCG</u> . See Red section for cystic fibrosis.	
4.9.1	Tolcapone	1, 5	NHSE commissioned.	
4.9.1	Tolcapone	1	Parkinson's Disease SCP	
6.5.2	Tolvaptan		SIADH Tolvaptan in the Syndrome of Inappropriate Anti-diuretic Hormone.	NICE TA358
8.3.4.1	Toremifene	1, 2	Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on	
			prescribing for a specified duration, for advice on drug management see: Referral and	
			Management Guidelines for Breast Cancer. See also, section on ibandronic acid.	
Unlicensed not	Treprostinil		Patients treated for Pulmonary Arterial Hypertension.	
listed in current		1, 5		
BNF				
	Tretinoin		Should not be prescribed in primary care as an oral anticancer medication, in line with	
8.1		1, 5	NPSA Alert. Exceptions include oral anti cancer medicines where a shared care	
			protocol exists.	
4.2.1	Trifluoperazine	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
8.3.4.2	Triptorelin Acetate 11.25mg	1, 2	Hormonal Management of Prostatic Cancer SCP.	
8.3.4.2	Triptorelin Pamoate 22.5mg	1, 2	Hormonal Management of Prostatic Cancer SCP.	
5.3.2	Valganciclovir	1, 5	NHSE commissioned.	
5.1.7	Vancomycin (oral)		If prescribed in line with NICE NG199 as a first line antibiotic for a first episode of mild,	NICE NG199
0		_	moderate or severe C.difficile infection. See also fidaxomicin in Amber section.	
7.4.5	Vardenafil	1, 2	If SLS critearia not met a GP may provide a private prescription (detailed in HSC	
	Vardenafil		<u>1999/148</u>). See also entry in green section. SLS criteria applies - prescriptions may be issued for patients eligible for NHS treatment	LISC 1000/177
7.4.5	varuenani		(as per SI 2004 No 629), otherwise RED. Note - Patients with Severe Distress are not	<u>HOC 1999/177</u>
			covered by SLS criteria (as detailed in HSC 1999/177).	
	Varenicline	_	Clients over 12 years and non-pregnant women should be signposted to the	
4.10.2		5	commissioned Stop Smoking service. http://sheffield.yorkshiresmokefree.nhs.uk/	
14.4	Varicella – Zoster vaccine (Zostavax®)	3	For routine vaccination against herpes zoster (shingles) other than in accordance with	
			the national programme for vaccinating those aged 70 to 79 years.	
5.3.3	Velpatasvir with sofosbuvir (Epclusa®)	1, 5	NHSE commissioned.	NICE TA430
5.3.3	Velpatasvir with sofosbuvir and voxilaprevir (Vosevi®)	1, 5	NHSE commissioned.	NICE TA507
	Venlafaxine at doses of 300 mg daily or above		Higher doses of venlafaxine have greater potential to exacerbate cardiac arrhythmias	
4.3.4		1, 2, 3	and hypertension.	
			See also venlafaxine in green section.	
5.2.1			SHSC have stated that they would not be routinely initiating prescriptions for modified	
	Venlafaxine modified and immediate release	_	release preparations. For total daily doses of 300mg or above see Amber section.	
8.1	Vinorelbine		Should not be prescribed in primary care as an oral anticancer medication, in line with	
		1, 5	<u>NPSA Alert.</u> Exceptions include oral anti cancer medicines where a shared care protocol exists.	
9.6.2	Vitamin P. Compound/Compound Strong/Complex	4	See <u>Sheffield STOP list</u> for full details. Thiamine should be used for patients at high risk	
9.0.2	Vitamin B Compound/Compound Strong/Complex	4	of developing Wernicke's encephalopathy.	
5.2.1	Voriconazole	1, 5	NHSE commissioned.	
0.2.1	VUICUIAZUIC	I, J		1

	Vortioxetine		NICE NG222 Depression in adults: treatment and management	NICE TA367
4.3.4				Vortioxetine for
				treating major
				depressive episodes
6.1.2.	Xultophy® (insulin degludec 100 unit per 1 ml , liraglutide	1, 2, 3	Also see amber section: insulin degludec.	
	3.6mg per 1 ml)			
14.4	Yellow fever (Travel vaccines administered exclusively for	4	See Sheffield STOP list for full details.	See local guidance
	the purpose of travel.)			for details of
				exceptions.
5.3.1	Zidovudine (including combinations)	1, 5	NHSE commissioned.	
4.2.1	Zuclopenthiixol	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
4.2.1	Zuclopenthiixol acetate	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	